Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Lilly

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Aripiprazole; Drug: Olanzapine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00088049

F1D-MC-HGLB

8047

Details and patient eligibility

About

The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female inpatient or outpatients, ages 18-65

Exclusion criteria

• Participation in a clinical trial of another drug including olanzapine or aripiprazole within 30 days prior to study entry (visit 1).
• Treatment with clozapine within the past 12 months.
• Have known uncorrected narrow-angle glaucoma.
• Have a diagnosis of Parkinson's disease, dementia or related disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind